Combined Therapeutics Inc., Cambridge, Massachusetts, has been selected as the North American winner of MilliporeSigma’s 2020 Advance Biotech Grant Program. The biotechnology company was selected for its innovative nucleic acid platform which, combined with virotherapy, has the potential to treat liver cancer by using a lipid nanoparticle delivery system.   “We help pioneering biotech companies bring lifesaving drugs to market, faster,” said Andrew Bulpin, head of Process Solutions at MilliporeS...